Yuli Wang
Department of Cancer Molecular Sciences
Pfizer Global Research and Development
Ann Arbor Laboratories
2800 Plymouth Road
USA
Name/email consistency: high
- A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. Wang, Y., Van Becelaere, K., Jiang, P., Przybranowski, S., Omer, C., Sebolt-Leopold, J. Neoplasia (2005)
- Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Wang, Y., Decker, S.J., Sebolt-Leopold, J. Cancer Biol. Ther. (2004)
- Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Wang, Y., Li, J., Booher, R.N., Kraker, A., Lawrence, T., Leopold, W.R., Sun, Y. Cancer Res. (2001)